Lung Cancer Clinical Trial
BMS-986012 in Relapsed/Refractory SCLC
Summary
The purpose of this study is to determine the safety, tolerability, pharmacokinetics, immunogenicity, antitumor activity and pharmacodynamics of BMS-986012 alone and in combination with nivolumab in patients with relapsed/refractory SCLC.
Eligibility Criteria
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
Histological or cytological confirmed small cell lung cancer (SCLC)
Performance Status 0-1
Adequate organ function
Measurable disease
Exclusion Criteria:
Known or suspected brain metastasis
Small cell cancer not lung in origin
Significant or acute medical illness
Uncontrolled or significant cardiac disease
Infection
≥ Grade 2 peripheral neuropathy
Concomitant malignancies
HIV related disease or known or suspected HIV+
Hepatitis B or C infection
ECG abnormalities as defined by the protocol
Allergies or hypersensitivities to monoclonal antibodies, BMS-986012 or related compounds, including fucosyl-GM1 vaccine and Nivolumab
Other protocol defined inclusion/exclusion criteria could apply
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 16 Locations for this study
New York New York, 10065, United States
Durham North Carolina, 27710, United States
Winston-Salem North Carolina, 27157, United States
St. Leonards New South Wales, 2065, Australia
Brisbane Queensland, 4102, Australia
Clayton Victoria, 3168, Australia
Gent , 9000, Belgium
Liege , 4000, Belgium
Edmonton Alberta, T6G 1, Canada
Halifax Nova Scotia, B3H 2, Canada
Hamilton Ontario, L8V 5, Canada
London Ontario, N6A 4, Canada
Toronto Ontario, M5G 2, Canada
Seoul , 03080, Korea, Republic of
Nijmegen , 6525 , Netherlands
San Juan , 00927, Puerto Rico
How clear is this clinincal trial information?